Evidence map›Paper›PMID 42215731›Full record

Trial reportNature cardiovascular research2026

Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction.

Mark Atallah, Nadim Nasrallah, Tarek Harb, Ines Valenta, Thomas H Schindler, Amelia S Wallace, Sotirios Tsimikas, Gary Gerstenblith, Thorsten M Leucker

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark AtallahDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nadim NasrallahDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tarek HarbDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ines ValentaDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Thomas H SchindlerDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Amelia S WallaceDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Sotirios TsimikasDivision of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Gary GerstenblithDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thorsten M LeuckerDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. tleucke1@jhmi.edu.ORCID http://orcid.org/0000-0003-2569-6617

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Localized myocardial inflammation after acute myocardial infarction (MI) is regulated by innate immune pathways. Oxidized phospholipids (OxPLs) carried on lipoprotein(a) (Lp(a)) are proinflammatory, but their association with myocardial inflammation during the early post-MI period has not been described. Here we study patients enrolled in a randomized, double-blind trial of in-hospital PCSK9 inhibition versus placebo, in whom this treatment decreased myocardial inflammation after MI. We analyze plasma levels of OxPLs on apolipoprotein B-100 containing lipoproteins (OxPL-apoB), OxPLs on apolipoprotein(a) (OxPL-apo(a)), and Lp(a) during hospital admission and at 30 days, and paired [

Indexed as

Lipoprotein(a)Myocardial InfarctionMyocarditisMyocardiumPhospholipidsAgedApolipoprotein B-100BiomarkersDouble-Blind MethodFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedOxidation-ReductionPositron-Emission TomographyApolipoprotein B-100BiomarkersFluorodeoxyglucose F18Lipoprotein(a)LPA protein, humanPhospholipidsProprotein Convertase 9Radiopharmaceuticals

Identifiers

PMID42215731

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.